{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:32:50Z","timestamp":1779114770833,"version":"3.51.4"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40272-022-00515-0","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T04:02:46Z","timestamp":1654747366000},"page":"307-319","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Management of Drug-Induced Epidermal Necrolysis (DEN) in Pediatric Patients: Moving from Drug-Induced Stevens\u2013Johnson Syndrome, Overlap and Toxic Epidermal Necrolysis to a Single Unifying Diagnosis of DEN"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9191-3611","authenticated-orcid":false,"given":"Michele L.","family":"Ramien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil H.","family":"Shear","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"515_CR1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","volume":"129","author":"S Bastuji-Garin","year":"1993","unstructured":"Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau J-C. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92\u20136.","journal-title":"Arch Dermatol"},{"issue":"2","key":"515_CR2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/bjd.20063","volume":"185","author":"ML Ramien","year":"2021","unstructured":"Ramien ML, Bahubeshi A, Lara-Corrales I, Pope E, Levy ML, Nopper AJ, et al. Blistering severe cutaneous adverse reactions in children: proposal for pediatric-focused clinical criteria. Br J Dermatol. 2021;185(2):447\u20139.","journal-title":"Br J Dermatol"},{"key":"515_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/pde.13383","volume":"35","author":"JW Antoon","year":"2018","unstructured":"Antoon JW, Goldman JL, Lee B, Schwartz A. Incidence, outcomes, and resource use in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. Pediatr Dermatol. 2018;35:182\u20137.","journal-title":"Pediatr Dermatol"},{"key":"515_CR4","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jaad.2016.12.024","volume":"76","author":"DY Hsu","year":"2017","unstructured":"Hsu DY, Brieva J, Silverberg NB, Paller AS, Silverberg JI. Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol. 2017;76:811-817.e4.","journal-title":"J Am Acad Dermatol"},{"key":"515_CR5","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.jid.2017.01.031","volume":"137","author":"N Frey","year":"2017","unstructured":"Frey N, Jossi J, Bodmer M, Bircher A, Jick SS, Meier CR, et al. The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. J Invest Dermatol. 2017;137:1240\u20137.","journal-title":"J Invest Dermatol"},{"key":"515_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3904\/kjim.2015.365","volume":"34","author":"M-S Yang","year":"2019","unstructured":"Yang M-S, Kim J-Y, Kang M-G, Lee S-Y, Jung J-W, Cho S-H, et al. Direct costs of severe cutaneous adverse reactions in a tertiary hospital in Korea. Korean J Intern Medicine. 2019;34:195\u2013201.","journal-title":"Korean J Intern Medicine."},{"key":"515_CR7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/pde.14118","volume":"37","author":"C Sibbald","year":"2020","unstructured":"Sibbald C, Putterman E, Micheletti R, Treat J, Castelo-Soccio L. Retrospective review of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis cases at a pediatric tertiary care institution. Pediatr Dermatol. 2020;37:461\u20136.","journal-title":"Pediatr Dermatol"},{"key":"515_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.iac.2004.03.012","volume":"24","author":"WJ Pichler","year":"2004","unstructured":"Pichler WJ. Immune mechanism of drug hypersensitivity. Immunol Allergy Clin N Am. 2004;24:373\u201397 (v-vi).","journal-title":"Immunol Allergy Clin N Am"},{"key":"515_CR9","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.jid.2016.11.034","volume":"137","author":"S-C Su","year":"2017","unstructured":"Su S-C, Mockenhaupt M, Wolkenstein P, Dunant A, Gouvello SL, Chen C-B, et al. Interleukin-15 is associated with severity and mortality in Stevens-Johnson syndrome\/toxic epidermal necrolysis. J Invest Dermatol. 2017;137:1065\u201373.","journal-title":"J Invest Dermatol"},{"key":"515_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/bjd.17841","volume":"181","author":"T McPherson","year":"2019","unstructured":"McPherson T, Exton LS, Biswas S, Creamer D, Dziewulski P, Newell L, et al. British Association of Dermatologists\u2019 guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in children and young people, 2018. Br J Dermatol. 2019;181:37\u201354.","journal-title":"Br J Dermatol"},{"key":"515_CR11","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/archdischild-2013-303718","volume":"98","author":"C Ferrandiz-Pulido","year":"2013","unstructured":"Ferrandiz-Pulido C, Garcia-Patos V. A review of causes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Arch Dis Child. 2013;98:998\u20131003.","journal-title":"Arch Dis Child"},{"key":"515_CR12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1542\/peds.2010-3322","volume":"128","author":"Y Finkelstein","year":"2011","unstructured":"Finkelstein Y, Soon GS, Acuna P, George M, Pope E, Ito S, et al. Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Pediatrics. 2011;128:723\u20138.","journal-title":"Pediatrics"},{"key":"515_CR13","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1542\/peds.2008-1923","volume":"123","author":"N Levi","year":"2009","unstructured":"Levi N, Bastuji-Garin S, Mockenhaupt M, Roujeau J-C, Flahault A, Kelly JP, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009;123:e297-304.","journal-title":"Pediatrics"},{"key":"515_CR14","doi-asserted-by":"publisher","first-page":"965","DOI":"10.2165\/00002018-200225130-00006","volume":"25","author":"R Forman","year":"2002","unstructured":"Forman R, Koren G, Shear NH. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years\u2019 experience. Drug Saf. 2002;25:965\u201372.","journal-title":"Drug Saf"},{"key":"515_CR15","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1001\/jamadermatol.2017.0160","volume":"153","author":"E Maverakis","year":"2017","unstructured":"Maverakis E, Wang EA, Shinkai K, Mahasirimongkol S, Margolis DJ, Avigan M, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis standard reporting and evaluation guidelines: results of a National Institutes of Health Working Group. JAMA Dermatol. 2017;153:587\u201392.","journal-title":"JAMA Dermatol"},{"key":"515_CR16","doi-asserted-by":"publisher","first-page":"3061084","DOI":"10.1155\/2018\/3061084","volume":"2018","author":"S Chatproedprai","year":"2018","unstructured":"Chatproedprai S, Wutticharoenwong V, Tempark T, Wananukul S. Clinical features and treatment outcomes among children with Stevens-Johnson Syndrome and toxic epidermal necrolysis: a 20-year study in a tertiary referral hospital. Dermatol Res Pract. 2018;2018:3061084\u20139.","journal-title":"Dermatol Res Pract"},{"key":"515_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/BCR.0000000000000208","volume":"36","author":"KP Quirke","year":"2015","unstructured":"Quirke KP, Beck A, Gamelli RL, Mosier MJ. A 15-year review of pediatric toxic epidermal necrolysis. J Burn Care Res. 2015;36:130\u20136.","journal-title":"J Burn Care Res"},{"key":"515_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/bcp.13445","volume":"84","author":"B Lebrun-Vignes","year":"2018","unstructured":"Lebrun-Vignes B, Guy C, Jean-Pastor M-J, Gras-Champel V, Zenut M, Drugs TFN of RC of P and the FI for ASR to. Is acetaminophen associated with a risk of Stevens-Johnson syndrome and toxic epidermal necrolysis? Analysis of the French Pharmacovigilance Database. Br J Clin Pharmacol. 2018;84:331\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"515_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/bmj.329.7457.101","volume":"329","author":"S Hettiaratchy","year":"2004","unstructured":"Hettiaratchy S, Papini R. Initial management of a major burn: II\u2014assessment and resuscitation. BMJ. 2004;329:101.","journal-title":"BMJ"},{"issue":"6","key":"515_CR20","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/pde.14324","volume":"37","author":"D Bhattarai","year":"2020","unstructured":"Bhattarai D, Vignesh P, Chaudhary H, Bharadwaj N, Saini L, Gupta K, et al. Epidermal necrolysis as the presenting manifestation of pediatric lupus. Pediatr Dermatol. 2020;37(6):1119\u201324.","journal-title":"Pediatr Dermatol"},{"key":"515_CR21","first-page":"6","volume":"135","author":"B Rzany","year":"1996","unstructured":"Rzany B, Hering O, Mockenhaupt M, Schr\u00f6der W, Goerttler E, Ring J, et al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 1996;135:6\u201311.","journal-title":"Br J Dermatol"},{"key":"515_CR22","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/j.jaad.2011.10.007","volume":"68","author":"L Valeyrie-Allanore","year":"2013","unstructured":"Valeyrie-Allanore L, Bastuji-Garin S, Gu\u00e9gan S, Ortonne N, Bagot M, Roujeau J-C, et al. Prognostic value of histologic features of toxic epidermal necrolysis. J Am Acad Dermatol. 2013;68:e29-35.","journal-title":"J Am Acad Dermatol"},{"key":"515_CR23","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/archderm.141.6.683","volume":"141","author":"AM Quinn","year":"2005","unstructured":"Quinn AM, Brown K, Bonish BK, Curry J, Gordon KB, Sinacore J, et al. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol. 2005;141:683\u20137.","journal-title":"Arch Dermatol"},{"key":"515_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","volume":"115","author":"N Fouchard","year":"2000","unstructured":"Fouchard N, Bertocchi M, Roujeau J-C, Revuz J, Wolkenstein P, Bastuji-Garin S. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149\u201353.","journal-title":"J Invest Dermatol"},{"key":"515_CR25","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1001\/jamadermatol.2018.5605","volume":"155","author":"MH Noe","year":"2019","unstructured":"Noe MH, Rosenbach M, Hubbard RA, Mostaghimi A, Cardones AR, Chen JK, et al. Development and validation of a risk prediction model for in-hospital mortality among patients with Stevens-Johnson syndrome\/toxic epidermal necrolysis\u2014ABCD-10. JAMA Dermatol. 2019;155:448\u201354.","journal-title":"JAMA Dermatol"},{"key":"515_CR26","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/BCR.0000000000000204","volume":"36","author":"A Beck","year":"2015","unstructured":"Beck A, Quirke KP, Gamelli RL, Mosier MJ. Pediatric toxic epidermal necrolysis: using SCORTEN and predictive models to predict morbidity when a focus on mortality is not enough. J Burn Care Res. 2015;36:167\u201377.","journal-title":"J Burn Care Res"},{"key":"515_CR27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/pde.13172","volume":"34","author":"J Sorrell","year":"2017","unstructured":"Sorrell J, Anthony L, Rademaker A, Belknap SM, Callahan S, West DP, et al. Score of toxic epidermal necrosis predicts the outcomes of pediatric epidermal necrolysis. Pediatr Dermatol. 2017;34:433\u20137.","journal-title":"Pediatr Dermatol"},{"key":"515_CR28","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.jid.2018.04.027","volume":"138","author":"RG Micheletti","year":"2018","unstructured":"Micheletti RG, Chiesa-Fuxench Z, Noe MH, Stephen S, Aleshin M, Agarwal A, et al. Stevens-Johnson syndrome\/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States. J Invest Dermatol. 2018;138:2315\u201321.","journal-title":"J Invest Dermatol"},{"key":"515_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/clpt.2009.252","volume":"88","author":"B Sassolas","year":"2010","unstructured":"Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88:60\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"515_CR30","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.jaip.2020.01.028","volume":"8","author":"C Toussaint","year":"2020","unstructured":"Toussaint C, Sanchez-Pena P, Titier K, Castaing N, Molimard M, Milpied B. Toxicological screening reveals toxic epidermal necrolysis likely carbamazepine-induced rather than idiopathic. J Allergy Clin Immunol Pract. 2020;8:2075\u20136.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"515_CR31","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/jdv.14890","volume":"32","author":"N Suthumchai","year":"2018","unstructured":"Suthumchai N, Srinoulprasert Y, Thantiworasit P, Rerknimitr P, Tuchinda P, Chularojanamontri L, et al. The measurement of drug-induced interferon \u03b3-releasing cells and lymphocyte proliferation in severe cutaneous adverse reactions. J Eur Acad Dermatol Venereol. 2018;32:992\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"515_CR32","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/bjd.14701","volume":"175","author":"J Klaewsongkram","year":"2016","unstructured":"Klaewsongkram J, Thantiworasit P, Suthumchai N, Rerknimitr P, Sukasem C, Tuchinda P, et al. In vitro test to confirm diagnosis of allopurinol-induced severe cutaneous adverse reactions. Br J Dermatol. 2016;175:994\u20131002.","journal-title":"Br J Dermatol"},{"key":"515_CR33","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fped.2020.00402","volume":"8","author":"L Liu","year":"2020","unstructured":"Liu L, Wang Y, Sun J, Wang W, Hou J, Wang X. Case report: clinical and immunological features of a Chinese cohort with mycoplasma-induced rash and mucositis. Front Pediatrics. 2020;8:402.","journal-title":"Front Pediatrics."},{"issue":"9","key":"515_CR34","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1034\/j.1398-9995.2003.00279.x","volume":"58","author":"W Aberer","year":"2003","unstructured":"Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy. 2003;58(9):84\u201393.","journal-title":"Allergy"},{"issue":"5","key":"515_CR35","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/cod.14063","volume":"86","author":"A Barbaud","year":"2022","unstructured":"Barbaud A, Castagna J, Soria A. Skin tests in the work-up of cutaneous adverse drug reactions: a review and update. Contact Dermatitis. 2022;86(5):344\u201356. https:\/\/doi.org\/10.1111\/cod.14063.","journal-title":"Contact Dermatitis."},{"key":"515_CR36","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1034\/j.1600-0536.2001.450601.x","volume":"45","author":"A Barbaud","year":"2001","unstructured":"Barbaud A, Gon\u00e7alo M, Bruynzeel D, Bircher A, Dermatitis ES of C. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis. 2001;45:321\u20138.","journal-title":"Contact Dermatitis"},{"key":"515_CR37","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/cod.12842","volume":"77","author":"H Assier","year":"2017","unstructured":"Assier H, Valeyrie-Allanore L, Gener G, Carvalh MV, Chosidow O, Wolkenstein P. Patch testing in non-immediate cutaneous adverse drug reactions: value of extemporaneous patch tests. Contact Dermatitis. 2017;77:297\u2013302.","journal-title":"Contact Dermatitis"},{"key":"515_CR38","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1600-0536.1996.tb02339.x","volume":"35","author":"CE Klein","year":"1996","unstructured":"Klein CE, Trautmann A, Zillikens D, Br\u00f6cker EB. Patch testing in an unusual case of toxic epidermal necrolysis. Contact Dermatitis. 1996;35:175\u20136.","journal-title":"Contact Dermatitis"},{"key":"515_CR39","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jaci.2018.10.030","volume":"143","author":"EJ Phillips","year":"2019","unstructured":"Phillips EJ, Bigliardi P, Bircher AJ, Broyles A, Chang Y-S, Chung W-H, et al. Controversies in drug allergy: testing for delayed reactions. J Allergy Clin Immun. 2019;143:66\u201373.","journal-title":"J Allergy Clin Immun"},{"key":"515_CR40","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.3390\/ijms18081737","volume":"18","author":"G Porebski","year":"2017","unstructured":"Porebski G. In vitro assays in severe cutaneous adverse drug reactions: are they still research tools or diagnostic tests already? Int J Mol Sci. 2017;18:1737.","journal-title":"Int J Mol Sci"},{"key":"515_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2021.113062","volume":"495","author":"G Porebski","year":"2021","unstructured":"Porebski G, Piotrowicz-Wojcik K, Spiewak R. ELISpot assay as a diagnostic tool in drug hypersensitivity reactions. J Immunol Methods. 2021;495: 113062.","journal-title":"J Immunol Methods"},{"key":"515_CR42","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/all.12886","volume":"71","author":"C Mayorga","year":"2016","unstructured":"Mayorga C, Celik G, Rouzaire P, Whitaker P, Bonadonna P, Rodrigues-Cernadas J, et al. In vitro tests for drug hypersensitivity reactions: an ENDA\/EAACI Drug Allergy Interest Group position paper. Allergy. 2016;71:1103\u201334.","journal-title":"Allergy"},{"key":"515_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045516","volume":"7","author":"M Fu","year":"2012","unstructured":"Fu M, Gao Y, Pan Y, Li W, Liao W, Wang G, et al. Recovered patients with Stevens-Johson syndrome and toxic epidermal necrolysis maintain Long-Lived IFN-\u03b3 and sFasL memory response. PLoS ONE. 2012;7: e45516.","journal-title":"PLoS ONE"},{"key":"515_CR44","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/cea.12145","volume":"43","author":"G Porebski","year":"2012","unstructured":"Porebski G, Pecaric-Petkovic T, Groux-Keller M, Bosak M, Kawabata TT, Pichler WJ. In vitro drug causality assessment in Stevens-Johnson syndrome\u2014alternatives for lymphocyte transformation test. Clin Exp Allergy. 2012;43:1027\u201337.","journal-title":"Clin Exp Allergy"},{"key":"515_CR45","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/clpt.2013.55","volume":"94","author":"U Amstutz","year":"2013","unstructured":"Amstutz U, Ross CJD, Castro-Pastrana LI, Rieder MJ, Shear NH, Hayden MR, et al. HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. Clin Pharmacol Ther. 2013;94:142\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"515_CR46","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/cpt.2008","volume":"109","author":"JH Karnes","year":"2021","unstructured":"Karnes JH, Rettie AE, Somogyi AA, Huddart R, Fohner AE, Formea CM, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2C9 and HLA-B Genotypes and phenytoin dosing: 2020 update. Clin Pharmacol Ther. 2021;109:302\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"515_CR47","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1177\/0884533608323434","volume":"23","author":"T Mayes","year":"2008","unstructured":"Mayes T, Gottschlich M, Khoury J, Warner P, Kagan R. Energy requirements of pediatric patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Nutr Clin Pract. 2008;23:547\u201350.","journal-title":"Nutr Clin Pract"},{"key":"515_CR48","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/BCR.0b013e3181cb8cb8","volume":"31","author":"S Shiga","year":"2010","unstructured":"Shiga S, Cartotto R. What are the fluid requirements in toxic epidermal necrolysis? J Burn Care Res. 2010;31:100\u20134.","journal-title":"J Burn Care Res"},{"key":"515_CR49","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S1081-1206(10)61112-X","volume":"94","author":"E Letko","year":"2005","unstructured":"Letko E, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed AR, Foster CS. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol. 2005;94:419\u201336 (quiz 436-8, 456).","journal-title":"Ann Allergy Asthma Immunol"},{"key":"515_CR50","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/00004630-200203000-00004","volume":"23","author":"TL Palmieri","year":"2002","unstructured":"Palmieri TL, Greenhalgh DG, Saffle JR, Spence RJ, Peck MD, Jeng JC, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. Burn Centers at the end of the twentieth Century. J Burn Care Rehabil. 2002;23:87\u201396.","journal-title":"J Burn Care Rehabil"},{"key":"515_CR51","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.jaad.2019.05.096","volume":"81","author":"HK Koh","year":"2019","unstructured":"Koh HK, Chai ZT, Tay HW, Fook-Chong S, Choo KJL, Oh CC, et al. Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: a cohort study of 176 patients. J Am Acad Dermatol. 2019;81:686\u201393.","journal-title":"J Am Acad Dermatol"},{"key":"515_CR52","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/bjd.14530","volume":"174","author":"D Creamer","year":"2016","unstructured":"Creamer D, Walsh SA, Dziewulski P, Exton LS, Lee HY, Dart JKG, et al. U.K. guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016;174:1194\u2013227.","journal-title":"Br J Dermatol"},{"key":"515_CR53","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJM197810262991703","volume":"299","author":"P Loirat","year":"1978","unstructured":"Loirat P, Rohan J, Baillet A, Beaufils F, David R, Chapman A. Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin. N Engl J Med. 1978;299:915\u20139.","journal-title":"N Engl J Med"},{"issue":"6","key":"515_CR54","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1093\/jbcr\/irab155","volume":"42","author":"PN Haravu","year":"2021","unstructured":"Haravu PN, Gottlieb LJ, Vrouwe SQ. Antishear therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis: a follow-up study. J Burn Care Res. 2021;42(6):1152\u201361.","journal-title":"J Burn Care Res"},{"key":"515_CR55","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/j.jaad.2018.05.1258","volume":"79","author":"HY Lee","year":"2018","unstructured":"Lee HY. Wound management strategies in Stevens-Johnson syndrome\/toxic epidermal necrolysis: an unmet need. J Am Acad Dermatol. 2018;79:e87\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"515_CR56","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s13671-020-00285-3","volume":"9","author":"JA Jaller","year":"2020","unstructured":"Jaller JA, McLellan BN, Balagula Y. Wound management in Stevens-Johnson syndrome and toxic epidermal necrolysis. Curr Dermatol Rep. 2020;9:58\u201372.","journal-title":"Curr Dermatol Rep"},{"key":"515_CR57","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/iwj.12938","volume":"15","author":"H Choi","year":"2018","unstructured":"Choi H, Castillo B, Seminario-Vidal L. Silver absorption in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis treated with silver-impregnated dressings. A case series. Int Wound J. 2018;15:1049\u201351.","journal-title":"Int Wound J"},{"key":"515_CR58","first-page":"9","volume":"39","author":"N Barea-Jim\u00e9nez","year":"2020","unstructured":"Barea-Jim\u00e9nez N, Calero J, Molina-Negr\u00f3n D, Del-Valle LML. Treatment for oral lesions in pediatric patients with Stevens-Johnson\u2019s syndrome: a case report and literature review. Int J Pediatr Dent. 2020;39:9.","journal-title":"Int J Pediatr Dent"},{"key":"515_CR59","doi-asserted-by":"publisher","first-page":"e07","DOI":"10.1111\/pde.13719","volume":"36","author":"AL Rocha","year":"2019","unstructured":"Rocha AL, Souza AFD, Nunes LFM, de Cunha NDS, Lanza CRM, Travassos DV, et al. Treatment of oral manifestations of toxic epidermal necrolysis with low-level laser therapy in a pediatric patient. Pediatric Dermatol. 2019;36:e07-30.","journal-title":"Pediatric Dermatol"},{"key":"515_CR60","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/j.jaad.2019.06.1299","volume":"82","author":"L Adams","year":"2020","unstructured":"Adams L, Creamer D. Controlling oral hemorrhages in Steven-Johnson syndrome\/toxic epidermal necrolysis. J Am Acad Dermatol. 2020;82:e3-4.","journal-title":"J Am Acad Dermatol"},{"key":"515_CR61","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ajo.2019.07.006","volume":"208","author":"SS Shanbhag","year":"2019","unstructured":"Shanbhag SS, Rashad R, Chodosh J, Saeed HN. Long-term effect of a treatment protocol for acute ocular involvement in Stevens-Johnson syndrome\/toxic epidermal necrolysis. Am J Ophthalmol. 2019;208:331\u201341.","journal-title":"Am J Ophthalmol"},{"key":"515_CR62","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ajo.2018.01.028","volume":"189","author":"S Basu","year":"2018","unstructured":"Basu S, Shanbhag SS, Gokani A, Kedar R, Bahuguna C, Sangwan VS. Chronic ocular sequelae of Stevens-Johnson syndrome in children: long-term impact of appropriate therapy on natural history of disease. Am J Ophthalmol. 2018;189:17\u201328.","journal-title":"Am J Ophthalmol"},{"key":"515_CR63","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/j.ophtha.2016.04.041","volume":"123","author":"DG Gregory","year":"2016","unstructured":"Gregory DG. New grading system and treatment guidelines for the acute ocular manifestations of Stevens-Johnson Syndrome. Ophthalmology. 2016;123:1653\u20138.","journal-title":"Ophthalmology"},{"key":"515_CR64","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ajo.2015.05.002","volume":"160","author":"C Sotozono","year":"2015","unstructured":"Sotozono C, Ueta M, Nakatani E, Kitami A, Watanabe H, Sueki H, et al. Predictive factors associated with acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Ophthalmol. 2015;160:228-237.e2.","journal-title":"Am J Ophthalmol"},{"key":"515_CR65","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jtos.2016.02.001","volume":"14","author":"S Kohanim","year":"2016","unstructured":"Kohanim S, Palioura S, Saeed HN, Akpek EK, Amescua G, Basu S, et al. Acute and chronic ophthalmic involvement in Stevens-Johnson syndrome\/Toxic epidermal necrolysis\u2014a comprehensive review and guide to therapy II. Ophthalmic disease. Ocular Surf. 2016;14:168\u201388.","journal-title":"Ocular Surf"},{"key":"515_CR66","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/ICU.0b013e3283622718","volume":"24","author":"JB Ciralsky","year":"2013","unstructured":"Ciralsky JB, Sippel KC, Gregory DG. Current ophthalmologic treatment strategies for acute and chronic Stevens-Johnson syndrome and toxic epidermal necrolysis. Curr Opin Ophthalmol. 2013;24:321\u20138.","journal-title":"Curr Opin Ophthalmol"},{"key":"515_CR67","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.ophtha.2015.10.027","volume":"123","author":"N Sharma","year":"2016","unstructured":"Sharma N, Thenarasun SA, Kaur M, Pushker N, Khanna N, Agarwal T, et al. Adjuvant Role of amniotic membrane transplantation in acute ocular Stevens-Johnson syndrome: a randomized control trial. Ophthalmology. 2016;123:484\u201391.","journal-title":"Ophthalmology"},{"key":"515_CR68","doi-asserted-by":"publisher","first-page":"490.e1","DOI":"10.1016\/j.jpurol.2017.01.018","volume":"13","author":"JPV Batavia","year":"2017","unstructured":"Batavia JPV, Chu DI, Long CJ, Jen M, Canning DA, Weiss DA. Genitourinary involvement and management in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Pediatr Urol. 2017;13:490.e1-490.e7.","journal-title":"J Pediatr Urol"},{"key":"515_CR69","first-page":"81","volume":"4","author":"DJ Kaser","year":"2011","unstructured":"Kaser DJ, Reichman DE, Laufer MR. Prevention of vulvovaginal sequelae in Stevens-Johnson syndrome and toxic epidermal necrolysis. Rev Obstetrics Gynecol. 2011;4:81\u20135.","journal-title":"Rev Obstetrics Gynecol."},{"key":"515_CR70","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0029-7844(97)00596-6","volume":"91","author":"E Meneux","year":"1998","unstructured":"Meneux E, Wolkenstein P, Haddad B, Roujeau JC, Revuz J, Paniel BJ. Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstetrics Gynecol. 1998;91:283\u20137.","journal-title":"Obstetrics Gynecol"},{"issue":"2","key":"515_CR71","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jaad.2019.08.031","volume":"85","author":"KF O\u2019Brien","year":"2021","unstructured":"O\u2019Brien KF, Bradley SE, Mitchell CM, Cardis MA, Mauskar MM, Pasieka HB. Vulvovaginal manifestations in Stevens-Johnson syndrome and toxic epidermal necrolysis: prevention and treatment. J Am Acad Dermatol. 2021;85(2):523\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"515_CR72","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jpag.2021.03.011","volume":"34","author":"M Holtz","year":"2021","unstructured":"Holtz M, Grimstad F, Higgins J, Denny G, Strickland J, Dowlut-McElroy T. Vulvovaginal involvement in pediatric Stevens-Johnson syndrome: a case series. J Pediatr Adol Gynec. 2021;34(5):745\u20138.","journal-title":"J Pediatr Adol Gynec."},{"key":"515_CR73","first-page":"e121","volume":"18","author":"BR Del Pozzo-Magana","year":"2011","unstructured":"Del Pozzo-Magana BR, Lazo-Langner A, Carleton B, Castro-Pastrana LI, Rieder MJ. A systematic review of treatment of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Popul Ther Clin Pharmacol. 2011;18:e121\u201333.","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"515_CR74","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jaip.2018.05.024","volume":"7","author":"JW Antoon","year":"2019","unstructured":"Antoon JW, Goldman JL, Shah SS, Lee B. A retrospective cohort study of the management and outcomes of children hospitalized with Stevens-Johnson syndrome or toxic epidermal necrolysis. J Allergy Clin Immunol Pract. 2019;7:244-250.e1.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"515_CR75","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jaad.2013.04.007","volume":"69","author":"K Hirahara","year":"2013","unstructured":"Hirahara K, Kano Y, Sato Y, Horie C, Okazaki A, Ishida T, et al. Methylprednisolone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers. J Am Acad Dermatol. 2013;69:496\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"515_CR76","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/1203475420982550","volume":"25","author":"C Olteanu","year":"2020","unstructured":"Olteanu C, Shear NH, Burnett M, Hashimoto R, Jeschke MG, Ziv M, et al. Retrospective study of patients with SJS\/TEN treated at a tertiary burn unit in Canada: overview of 17 years of treatment. J Cutan Med Surg. 2020;25:271\u201380.","journal-title":"J Cutan Med Surg"},{"key":"515_CR77","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/JIR.S160964","volume":"11","author":"QX Ng","year":"2018","unstructured":"Ng QX, Deyn MLZQD, Venkatanarayanan N, Ho CYX, Yeo W-S. A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome\/toxic epidermal necrolysis. J Inflamm Res. 2018;11:135\u201342.","journal-title":"J Inflamm Res"},{"key":"515_CR78","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.dsi.2017.04.004","volume":"35","author":"Y-T Chen","year":"2017","unstructured":"Chen Y-T, Hsu C-Y, Chien Y-N, Lee W-R, Huang Y-C. Efficacy of cyclosporine for the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: Systemic review and meta-analysis. Dermatol Sin. 2017;35:131\u20137.","journal-title":"Dermatol Sin"},{"key":"515_CR79","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jaad.2014.07.016","volume":"71","author":"MG Kirchhof","year":"2014","unstructured":"Kirchhof MG, Miliszewski MA, Sikora S, Papp A, Dutz JP. Retrospective review of Stevens-Johnson syndrome\/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol. 2014;71:941\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"515_CR80","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/pde.13236","volume":"34","author":"JS John","year":"2017","unstructured":"John JS, Ratushny V, Liu KJ, Bach DQ, Badri O, Gracey LE, et al. Successful use of cyclosporin a for stevens-johnson syndrome and toxic epidermal necrolysis in three children. Pediatr Dermatol. 2017;34:540\u20136.","journal-title":"Pediatr Dermatol"},{"key":"515_CR81","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1365-2133.2012.10965.x","volume":"167","author":"Y-C Huang","year":"2012","unstructured":"Huang Y-C, Li Y-C, Chen T-J. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br J Dermatol. 2012;167:424\u201332.","journal-title":"Br J Dermatol"},{"key":"515_CR82","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1468-3083.2010.03935.x","volume":"25","author":"C Ferr\u00e1ndiz-Pulido","year":"2011","unstructured":"Ferr\u00e1ndiz-Pulido C, Garc\u00eda-Fern\u00e1ndez D, Dom\u00ednguez-Sampedro P, Garc\u00eda-Patos V, Ferrandiz-Pulido C, Garcia-Fernandez D, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of the experience with paediatric patients in a university hospital. J Eur Acad Dermatol. 2011;25:1153\u20139.","journal-title":"J Eur Acad Dermatol"},{"key":"515_CR83","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jaad.2009.06.085","volume":"62","author":"MJ-A Koh","year":"2010","unstructured":"Koh MJ-A, Tay Y-K. Stevens-Johnson syndrome and toxic epidermal necrolysis in Asian children. J Am Acad Dermatol. 2010;62:54\u201360.","journal-title":"J Am Acad Dermatol"},{"key":"515_CR84","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1172\/JCI93349","volume":"128","author":"C-WW Wang","year":"2018","unstructured":"Wang C-WW, Yang L-YY, Chen C-BB, Ho H-CC, Hung S-II, Yang C-HH, et al. Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018;128:985\u201396.","journal-title":"J Clin Invest"},{"key":"515_CR85","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1001\/jamadermatol.2019.3731","volume":"156","author":"P Eliades","year":"2020","unstructured":"Eliades P, Fonseca M, Harp J. Use of etanercept in a series of pediatric patients with Stevens-Johnson syndrome-toxic epidermal necrolysis spectrum disease. JAMA Dermatol. 2020;156:921\u20132.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"515_CR86","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.jaad.2020.12.080","volume":"85","author":"M Sachdeva","year":"2021","unstructured":"Sachdeva M, Mufti A, Kim P, Maliyar K, Sibbald C. Biologic treatment in pediatric Stevens-Johnson syndrome\/toxic epidermal necrolysis: a systematic review. J Am Acad Dermatol. 2021;85(4):1011\u20133.","journal-title":"J Am Acad Dermatol"},{"key":"515_CR87","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1111\/jdv.17469","volume":"35","author":"L Giraud-Kerleroux","year":"2021","unstructured":"Giraud-Kerleroux L, Bellon N, Welfringer-Morin A, Leclerc-Mercier S, Costedoat I, Coquin J, et al. Childhood epidermal necrolysis and erythema multiforme major: a multicentre French cohort study of 62 patients. J Eur Acad Dermatol. 2021;35:2051\u20138.","journal-title":"J Eur Acad Dermatol"},{"key":"515_CR88","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jaip.2017.01.025","volume":"5","author":"JG Peter","year":"2017","unstructured":"Peter JG, Lehloenya R, Dlamini S, Risma K, White KD, Konvinse KC, et al. Severe delayed cutaneous and systemic reactions to drugs: a global perspective on the science and art of current practice. J Allergy Clin Immunol Pract. 2017;5:547\u201363.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"515_CR89","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/bjd.20741","volume":"186","author":"J Forsyth","year":"2022","unstructured":"Forsyth J, Russell E, McPherson T. A retrospective case series of paediatric Stevens-Johnson syndrome and toxic epidermal necrolysis: evaluation of practice using the British Association of Dermatology\u2019s National Guidelines for children and young people. Br J Dermatol. 2022;186:197\u20138.","journal-title":"Br J Dermatol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-022-00515-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-022-00515-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-022-00515-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T03:41:38Z","timestamp":1655523698000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-022-00515-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":89,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["515"],"URL":"https:\/\/doi.org\/10.1007\/s40272-022-00515-0","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]},"assertion":[{"value":"26 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Michele Ramien has received research funding from the Pediatric Dermatology Research Alliance for a project on pediatric SJS-TEN. Danny Mansour and Neil Shear have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors consent to publication of this work.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MR drafted and revised the manuscript. DM and NS critically reviewed and revised the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}